Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Accumulated Expenses: 2019-2025

Historic Other Accumulated Expenses for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $14.6 million.

  • Kymera Therapeutics' Other Accumulated Expenses rose 15.41% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 15.41%. This contributed to the annual value of $17.8 million for FY2024, which is 17.90% up from last year.
  • Kymera Therapeutics' Other Accumulated Expenses amounted to $14.6 million in Q3 2025, which was down 12.69% from $16.7 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Other Accumulated Expenses registered a high of $17.8 million during Q4 2024, and its lowest value of $8.0 million during Q1 2024.
  • In the last 3 years, Kymera Therapeutics' Other Accumulated Expenses had a median value of $12.6 million in 2024 and averaged $13.3 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Other Accumulated Expenses spiked by 232.18% in 2021, and later plummeted by 32.17% in 2023.
  • Kymera Therapeutics' Other Accumulated Expenses (Quarterly) stood at $15.2 million in 2021, then increased by 11.91% to $17.0 million in 2022, then declined by 11.05% to $15.1 million in 2023, then rose by 17.90% to $17.8 million in 2024, then grew by 15.41% to $14.6 million in 2025.
  • Its last three reported values are $14.6 million in Q3 2025, $16.7 million for Q2 2025, and $14.1 million during Q1 2025.